Nicola Fusco, Director of Biobank for Translational and Digital Medicine Unit, Laboratory of Pathological Anatomy (Histology and NGS Molecular Diagnostics), and Division of Pathology at IEO European Institute of Oncology, shared a post on LinkedIn:
“We are pleased to share our recent perspective published in Virchows Archiv Springer Nature: “Immunohistochemistry for PTEN testing in HR+/HER2– metastatic breast.”
PTEN loss is emerging as a key biomarker in HR+/HER2– metastatic breast cancer, particularly in the setting of AKT inhibitors such as Capivasertib.
While NGS remains the gold standard, immunohistochemistry (IHC) provides a pragmatic and accessible alternative, especially when tissue or infrastructure is limited.
Together with Umberto Malapelle, Elena Guerini Rocco, and Isabella Castellano we provide in this article fresh information on the clinical utility of PTEN IHC for guiding targeted therapies and highlight evidence from the CAPItello-291 study, supporting PTEN deficiency (defined as <10% staining) as predictive. We also propose best practices and reporting standards.
With ~10% of samples in major clinical trials compromised for NGS, IHC can still play a role in bridging diagnostic gaps for these patients.”
Title: Immunohistochemistry for PTEN testing in HR +/HER2˗ metastatic breast cancer
Authors: Nicola Fusco, Elena Guerini-Rocco, Isabella Castellano and Umberto Malapelle
Read The Full Article at Virchows Archiv Springer Nature.
More posts featuring Nicola Fusco.